BUFFALO, NY--(Marketwired - Feb 5, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company is scheduled to present at the 2015 BIO CEO & Investor Conference, February 9-10, in New York, NY.

Yakov Kogan, Ph.D., Chief Executive Officer of Cleveland BioLabs, will present the Company's oncology and biodefense programs on February 10 at 2:00 p.m. ET. A live and archived webcast of the Company's presentation will be available on the investor page of the Cleveland BioLabs website at www.cbiolabs.com.

About Cleveland BioLabs
Cleveland BioLabs, Inc. is an innovative biopharmaceutical company seeking to develop first-in-class pharmaceuticals designed to address diseases with significant medical need. The company's lead product candidates are entolimod, which is being developed as radiation countermeasure and a potential cancer treatment, and Curaxin CBL0137, our lead oncology product candidate. The company conducts business in the United States and in the Russian Federation through our three operating subsidiaries, Incuron, LLC, BioLabs 612, LLC and Panacela Labs, Inc. The company maintains strategic relationships with the Cleveland Clinic, Roswell Park Cancer Institute, and the Children's Cancer Institute Australia. To learn more about Cleveland BioLabs, Inc., please visit the Company's website at http://www.cbiolabs.com.